• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Oncology - Articles and news items

esmo-2016-banner

ESMO 2016: New data from Eisai’s oncology portfolio for halaven (eribulin), lenvima (lenvatinib) and kisplyx (lenvatinib)

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here’s a preview snippet…

collabs

Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

Bristol-Myers’ Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy…

HTL1071

Initiation of HTL1071 trial triggers $10m payment to Heptares

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares…

yeliva

Positive results for Yeliva in Phase I advanced solid tumour study

Industry news / 4 July 2016 / Victoria White, Digital Content Producer

Yeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities…

xilonix

Xilonix demonstrates significant clinical response in colorectal cancer study

Industry news / 4 July 2016 / Victoria White, Digital Content Producer

XBiotech’s Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralise interleukin-1 alpha (IL-1α)…

enadenotucirev

BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients…

urological cancers market

Global urological cancers market to double by 2022, says GBI Research

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research…

regorafenib

Regorafenib increases overall survival in hepatocellular carcinoma study

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced…

bispecific antibodies

Novartis and Xencor enter bispecific antibody collaboration

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies…

immunotherapy

Cancer immunotherapy drugs linked to autoimmune diseases

Industry news / 24 June 2016 / Victoria White, Digital Content Producer

Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases…

INCAGN1876

Phase I/II trial of INCAGN1876 in solid tumours starts

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1876 in patients with solid tumours…

brca1

Denosumab may prevent breast cancer in women with BRCA1 gene mutation

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Researchers have discovered that an existing medication, denosumab, may prevent breast cancer in women carrying a faulty BRCA1 gene…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +